BioVersys Advances AlpE into Phase 2b TB Trial with GSK

Event summary

  • BioVersys dosed the first patient in a Phase 2b trial of AlpE for pulmonary tuberculosis, in collaboration with GSK under the UNITE4TB project.
  • The trial will evaluate AlpE in combination with first-line TB drugs (RZE) for two months, followed by RH alone for 18 weeks.
  • Results from the Phase 2b trial are expected by the end of 2027.
  • BioVersys plans to initiate a Phase 2 trial for TB meningitis in H1 2026.

The big picture

BioVersys' advancement of AlpE into Phase 2b trials marks a critical step in developing new treatments for tuberculosis, a disease that remains a significant global health threat. The collaboration with GSK and the UNITE4TB project underscores the importance of public-private partnerships in accelerating the development of novel antibiotics. With the rising prevalence of drug-resistant TB, the success of AlpE could represent a major breakthrough in addressing this public health crisis.

What we're watching

Trial Outcomes
Whether AlpE demonstrates sufficient efficacy and safety in the Phase 2b trial to progress to Phase 3.
Regulatory Pathway
The pace at which AlpE could secure full approval from the FDA and EMA, given its orphan-drug designation.
Market Potential
How AlpE's novel mechanism could address the growing challenge of drug-resistant TB, particularly in high-burden countries.